Rockefeller Capital Management’s Aquestive Therapeutics AQST Stock Holding History
Bought
Maintained
Sold
Other funds holding AQST
BCM
Rockefeller Capital Management's AQST Position: Q3 2026 in Review
Rockefeller Capital Management reduced its Aquestive Therapeutics (AQST) stake by 9.7% in Q3 2026, selling an estimated $7.13K and leaving 15,000 shares worth $69.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3277.
Rockefeller Capital Management first reported a position in AQST in Q3 2020 and has held it in 15 quarters since. The position peaked at $198K in Q3 2025. 190 funds tracked by Wall St. Rank hold AQST as of Q3 2026.
- Rockefeller Capital Management held 15,000 shares of Aquestive Therapeutics worth $69.4K as of Q3 2026.
- Rockefeller Capital Management sold 1,604 Aquestive Therapeutics shares in Q3 2026, an estimated $7.13K.
- Aquestive Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3277 holding.
- Rockefeller Capital Management first reported a position in Aquestive Therapeutics in Q3 2020 and has held it in 15 quarters since.
- Rockefeller Capital Management's Aquestive Therapeutics position peaked at $198K in Q3 2025.
- 190 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.